{
    "2019-04-13": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Phase 2 Study",
                        "20-Valent Pneumococcal Conjugate Vaccine",
                        "Prevention",
                        "Invasive Disease",
                        "Pneumonia",
                        "Adults"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}